• Dual Terminal Oxidase Inhibition in Tuberculosis by Pretoman

  2026-04-25

  This study defines how pretomanid, a bicyclic nitroimidazole derivative, achieves potent bactericidal activity against Mycobacterium tuberculosis by inhibiting both cytochrome bcc:aa3 and bd terminal oxidases. The findings highlight the value of rational combination regimens targeting respiratory metabolism to suppress resistance and enhance efficacy in tuberculosis therapy.

• Applied Workflows with Hesperadin: Aurora B Kinase Inhibitor

  2026-04-24

  Hesperadin enables targeted disruption of mitotic progression and spindle assembly checkpoint fidelity, offering a robust platform for mechanistic cancer research and cell cycle dissection. This article delivers actionable protocols, troubleshooting strategies, and a translational bridge from recent checkpoint complex regulation discoveries.

• ATF4-Regulated Enhancer Inhibition Mitigates Liver Fibrosis

  2026-04-24

  This study uncovers a non-canonical, ATF4-driven enhancer program in hepatic stellate cells that promotes liver fibrosis, independent of classic ER stress pathways. Targeting ATF4 translation, the researchers demonstrate meaningful reversal of fibrosis, highlighting new molecular targets for future therapeutic development.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-23

  Schwartz's dissertation redefines how in vitro assays distinguish between cancer cell death and growth inhibition, demonstrating that relative and fractional viability capture distinct drug effects. These insights clarify the interpretation of apoptosis assays, supporting more precise evaluation of agents like ABT-263 (Navitoclax) in preclinical models.

• Optimizing Cell Selection with Geneticin, G-418 Sulfate (SKU

  2026-04-23

  This article delivers practical, evidence-based strategies for leveraging Geneticin, G-418 Sulfate (SKU A2513) to resolve real-world challenges in cell selection, viability assays, and antiviral research. By drawing on quantitative data and scenario-driven Q&A, we demonstrate how APExBIO’s Geneticin ensures reproducibility and sensitivity in advanced biomedical workflows.

• Disrupting the c-MYC-G9a Axis: Co-targeting BRD4 and RAC1 in

  2026-04-22

  This study demonstrates that co-inhibition of BRD4 and RAC1 suppresses growth, stemness, and tumorigenesis in diverse breast cancer subtypes by disrupting the c-MYC–G9a–FTH1 signaling axis and downregulating HDAC1. The findings reveal a mechanistic link between oncogenic signaling and epigenetic chromatin remodeling, providing a rationale for targeting these pathways in translational cancer research.

• CDK9 Inhibitor (A3294): Technical Use and Protocol Guidance

  2026-04-22

  The CDK9 inhibitor (A3294) offers researchers a selective, non-cytotoxic tool for precise inhibition of cyclin dependent kinase 9 activity in studies of transcription elongation and HIV-1 propagation. It is not intended for experiments requiring broad-spectrum CDK inhibition or long-term storage of working solutions. Rigorous adherence to protocol and quality parameters ensures reliable results in laboratory workflows.

• ISRIB (trans-isomer): Precision PERK Inhibitor for ER Stress

  2026-04-21

  ISRIB (trans-isomer) stands out as a next-generation PERK inhibitor, enabling precise dissection of the integrated stress response in models ranging from liver fibrosis to neurodegeneration. Its potent action on eIF2B activation and ATF4 suppression allows researchers to unravel disease mechanisms and optimize translational workflows.

• In Situ CAR Macrophage Programming via mRNA-LNP for Peritone

  2026-04-21

  This study demonstrates a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) platform for intraperitoneal programming of chimeric antigen receptor macrophages (CAR-Ms) to treat peritoneal metastases. By evaluating 36 CAR designs, the authors identify strategies for robust immune activation and improved synergy with checkpoint blockade, advancing solid tumor immunotherapy.

• PNU 74654: Precision Wnt Signaling Pathway Inhibitor Workflo

  2026-04-20

  PNU 74654 stands out for its targeted, high-purity inhibition of the Wnt/β-catenin pathway, making it invaluable for dissecting cell proliferation and differentiation mechanisms in cancer and stem cell research. This article translates cutting-edge findings into actionable workflows, troubleshooting tips, and advanced applications for maximizing reproducibility and specificity.

• ABT-263 (Navitoclax): Applied Workflows for Apoptosis Resear

  2026-04-20

  ABT-263 (Navitoclax) empowers oncology researchers to dissect Bcl-2-mediated apoptosis, overcome chemoresistance, and streamline apoptosis assays across pediatric and adult cancer models. This practical guide details optimized protocols, troubleshooting strategies, and translational insights to maximize assay reliability and biological impact.

• Crizotinib Hydrochloride: Transforming Tumor Modeling in Onc

  2026-04-19

  This thought-leadership article examines the mechanistic and strategic value of Crizotinib hydrochloride in translational cancer research. We explore its role as an ALK kinase inhibitor in advanced patient-derived assembloid models, connecting biological rationale, experimental evidence, and workflow optimization. The piece contextualizes APExBIO's Crizotinib hydrochloride within the evolving landscape of preclinical tumor modeling, referencing recent breakthroughs and best practices for translational researchers.

• Vorinostat (SAHA): HDAC Inhibition and Epigenetic Modulation

  2026-04-18

  Vorinostat (suberoylanilide hydroxamic acid) is a potent HDAC inhibitor used in epigenetic modulation for oncology research. It induces apoptosis via intrinsic pathways and demonstrates efficacy across several cancer cell lines. This article details its mechanism, benchmarks, and workflow integration, emphasizing machine-readable evidence.

• Transforming Mucin Detection: Strategic Guidance with Alcian

  2026-04-17

  This article provides translational researchers with a mechanistic and workflow-optimized perspective on mucin and mucosubstance detection using the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5. Grounded in recent literature and comparative studies, it bridges foundational biology, experimental best practices, and future-oriented strategy for stem cell and tissue research.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-04-16

  This study introduces a novel gastric cancer assembloid model that integrates patient-matched tumor organoids with stromal cell subpopulations, recapitulating the cellular heterogeneity of primary tumors. The approach enhances drug response prediction and provides a robust platform for investigating tumor–stroma interactions and resistance mechanisms.

16184 records 1/1079 page Next 12345 下5页 Last page